Ainos, Inc. (NASDAQ:AIMD) Short Interest Update

Ainos, Inc. (NASDAQ:AIMDGet Free Report) was the recipient of a large growth in short interest during the month of July. As of July 31st, there was short interest totaling 21,299 shares, a growth of 50.0% from the July 15th total of 14,197 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average daily trading volume, of 36,032 shares, the days-to-cover ratio is presently 0.6 days.

Ainos Stock Performance

Shares of NASDAQ:AIMD opened at $1.42 on Tuesday. Ainos has a one year low of $1.26 and a one year high of $4.44. The stock has a market capitalization of $10.49 million, a price-to-earnings ratio of -0.56 and a beta of 2.46. The company has a 50-day simple moving average of $1.69 and a 200-day simple moving average of $1.71.

Ainos (NASDAQ:AIMDGet Free Report) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.62) earnings per share (EPS) for the quarter. The company had revenue of $0.15 million for the quarter. Ainos had a negative return on equity of 217.50% and a negative net margin of 11,912.10%.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Ainos from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, May 26th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Ainos currently has a consensus rating of “Sell”.

View Our Latest Report on AIMD

Insider Buying and Selling

In other Ainos news, major shareholder Carbon Nano Technology Taiwan sold 41,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $2.36, for a total value of $96,760.00. Following the completion of the sale, the insider owned 948,925 shares in the company, valued at approximately $2,239,463. The trade was a 4.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Chun-Jung Tsai sold 27,718 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $1.87, for a total value of $51,832.66. Following the completion of the sale, the director directly owned 658,199 shares of the company’s stock, valued at $1,230,832.13. The trade was a 4.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have bought 7,500 shares of company stock worth $15,435 and have sold 179,788 shares worth $359,247. 9.79% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Mariner LLC purchased a new position in shares of Ainos in the 4th quarter valued at approximately $37,000. Two Sigma Investments LP purchased a new stake in shares of Ainos during the third quarter worth approximately $80,000. DRW Securities LLC raised its stake in shares of Ainos by 272.6% during the fourth quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock worth $109,000 after purchasing an additional 48,439 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in shares of Ainos by 13.1% during the fourth quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock worth $109,000 after purchasing an additional 7,700 shares during the period.

About Ainos

(Get Free Report)

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.

See Also

Receive News & Ratings for Ainos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ainos and related companies with MarketBeat.com's FREE daily email newsletter.